CoChat

The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)

Open access
Greenberg, Paul, Chitnis, Abhishek, Louie, Derek, Suthoff, Ellison, Chen, Shih-Yin, Maitland, Jessica, Gagnon-Sanschagrin, Patrick, Fournier, Andree-Anne, Kessler, Ronald C. · 2023 · Advances in Therapy

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 6 of the 21 sources its claims cite were checked for support.

Abstract

INTRODUCTION: Previous societal burden estimations for major depressive disorder (MDD) often fail to account for several hidden cost components. This study provides a comprehensive evaluation of societal costs for adults with MDD in the United States (USA) in 2019. The potential impact of a more effective, rapid-acting MDD therapy vs standard of care on the economic burden of MDD was estimated to illustrate the utility of such a framework in evaluating new interventions. METHODS: This study used a prevalence-based human capital approach. Incremental costs (2019 US dollars) per individual with MDD were derived from national survey inputs and published literature and included incremental healthcare costs and indirect costs. For each cost component, the societal costs were extrapolated by multiplying the per-patient costs by the number of individuals with MDD. The impact of a more effective, rapid-acting novel therapy on the economic burden of MDD was then simulated on the basis of these inputs. RESULTS: In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD. The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%). In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months. CONCLUSIONS: The economic burden of MDD is substantial and extends beyond healthcare costs, underscoring the impact of MDD across multiple aspects of life. Such a broad societal perspective should be considered in assessing the impact of the advent of effective, rapid-acting MDD therapies.

Overview

CoChat Summary

TL;DR

This study estimates the 2019 societal economic burden of major depressive disorder (MDD) among US adults at $333.7 billion, or $16,854 per adult with MDD, with most costs driven by indirect components. A hypothetical simulation suggests a more effective, rapid-acting therapy could reduce the incremental economic burden by 7.7%.

Key findings

  • The total incremental economic burden of MDD in US adults in 2019 was $333.7 billion ($382.4 billion in 2023 USD), or $16,854 per adult with MDD; indirect costs accounted for 61.9% ($206.4 billion) of the total.
  • Household-related costs were $80.1 billion (24.0% of total burden), representing 38.8% of all indirect costs and borne by adults without MDD living with an adult with MDD.
  • MDD prevalence among US adults was 7.8%, equivalent to 19.8 million adults; 67.1% had moderate and 32.9% had severe symptoms, and 62.7% of the MDD population were female.
  • In a simulation assuming a novel therapy with early response of 50.0% versus 19.8% for standard care, the incremental economic burden fell to $308.0 billion, a 7.7% reduction; sensitivity analyses ranged from $254.4 billion to $418.6 billion.

Methods

  • Prevalence-based human capital approach using a bottom-up method: average per-patient incremental costs were multiplied by the estimated number of US adults with MDD.
  • Cost components included healthcare costs, unemployment, absenteeism, presenteeism, disability, all-cause mortality, and household-related costs, stratified by gender and MDD severity where available.
  • Inputs came from national survey data (NSDUH, NHANES), US Census Bureau data, claims-based studies, and published literature; a hypothetical simulation assessed the impact of a rapid-acting novel MDD therapy.

Limitations

  • The paper states that cost estimates should be interpreted as associations rather than causation, and that reliance on multiple literature-based estimates may under- or overestimate certain cost components.
  • The paper states that MDD prevalence used NSDUH major depressive episode data as a proxy, with possible self-report bias, and that individuals with mild depressive symptoms (PHQ-9 score <10) were assumed not to qualify for MDD, potentially missing some burden.
  • The paper states that the novel therapy simulation was hypothetical, assumed all treated patients would switch to the novel therapy, and did not account for long-term life-course effects; the text also makes evident that the study was funded by Biogen Inc. and Sage Therapeutics, Inc., with several authors employed by or consulting for industry.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12325-023-02622-x

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 MDD population in the USA in 2019a. MDD, major depressive disorder; MDE, major depressive episode; NHANES, National Health and Nutrition Examination Survey; NSDUH, National Survey on Drug Use and Health; PHQ-9, Patient Health Questionnaire-9. a The severity of MDD was based on the proportion of patients with moderate to severe depression symptoms, which was defined using the PHQ-9 categories of moderate (score 10–14) and severe (score ≥ 15). Of note, the severity proportions were applied to the population of adults with MDD under the assumption that patients with at least 1 MDE in the past year (definition in the NSDUH) are represented by patients with PHQ-9 score of ≥ 10 (definition of moderate and severe MDD in NHANES). Therefore, it was assumed that no patients with mild depressive symptoms (PHQ-9 score of < 10) would qualify for MDD
Fig. 1 MDD population in the USA in 2019a. MDD, major depressive disorder; MDE, major depressive episode; NHANES, National Health and Nutrition Examination Survey; NSDUH, National Survey on Drug Use and Health; PHQ-9, Patient Health Questionnaire-9. a The severity of MDD was based on the proportion of patients with moderate to severe depression symptoms, which was defined using the PHQ-9 categories of moderate (score 10–14) and severe (score ≥ 15). Of note, the severity proportions were applied to the population of adults with MDD under the assumption that patients with at least 1 MDE in the past year (definition in the NSDUH) are represented by patients with PHQ-9 score of ≥ 10 (definition of moderate and severe MDD in NHANES). Therefore, it was assumed that no patients with mild depressive symptoms (PHQ-9 score of < 10) would qualify for MDDCC BY-NC · PubMed Central
Fig. 2 Percentage breakdown of cost components ($US, billion)
Fig. 2 Percentage breakdown of cost components ($US, billion)CC BY-NC · PubMed Central

Verification

Claims the paper makes

3 Valid · 3 Not valid · 13 Not checked · 62 Own results and interpretations

48 more claims

Create a free account to see all 81 claims and to verify the 15 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 17
  • The quote only partly states this claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 30 references

Research works printed but not linked: 2

  1. Voller C, Hickey C, Tan R, et al. Assessing the onset of efficacy and tolerability of pharmacological treatments in major depressive disorder: a systematic literature review and descriptive analysis. [unpublished manuscript]. 2023.
  2. Chitnis A, O’Callaghan L, Fournier AA, et al. Impact of living with an adult with major depressive disorder among households in the United States. J Affect Disord. 2023. (in press).

Cited by

See all 264

Metadata

Authors
Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S.-Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A.-A., & Kessler, R. C.
Affiliations
  • Analysis Group (United States) (US)
  • Biogen (United States) (US)
  • Sage Therapeutics (United States) (US)
  • Harvard University (US)
Corresponding author
Maitland, Jessica
Venue
Advances in Therapy
Published
2023-07-31
Volume
40
Issue
10
Pages
4460-4479
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W4385396235
Cited by
223
References
30
Citations by year
2026: 90 · 2025: 89 · 2024: 35 · 2023: 3
FWCI
64.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Biogen
  • Sage Therapeutics
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
major depressive disorder, economic burden, social costs, health care costs, indirect costs, presenteeism, absenteeism, household costs, rapid-acting antidepressants, cost-effectiveness, prevalence, United States
MeSH terms
Financial Stress, Adult, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Male, United States, Prevalence, Health Care Costs, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). https://app.cochat.ai/papers/10.1007/s12325-023-02622-x
The paper
Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S.-Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A.-A., & Kessler, R. C. (2023). The Economic Burden of Adults with Major Depressive Disorder in the United States (2019). Advances in Therapy. https://doi.org/10.1007/s12325-023-02622-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.